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Summary
Transgenic murine lines have been constructed that express a chimeric class I molecule composed
of the cx1 and u2 domains of HLAA2.1 and the 0, transmembrane, and cytoplasmic domains
of H-2Kb. Upon immunization with influenza virus, transgenic mice developed a strong A2.1Kb-
restricted cytotoxic T lymphocyte (CTL) response specific for the same matrix protein epitope
that serves as the dominant A2.1-restricted determinant in the equivalent human response. Fine
specificity analysis of CTL clones using truncated peptides revealed strong similarity between
the response repertoire of transgenic mice and that previously reported using influenza-specific
A2.1-restricted CTL clones from humans. This suggests that even when considering T cell responses
by different species, the a1 and ot2 domains of the restriction element play a dominant role in
determining the CTL specific repertoire. Thus, substituting the a3 domain of A2.1 with a murine
counterpart has permitted development of a transgenic strain that should serve as an excellent
model system in studies of HLArestricted responses.
M
HC-encoded molecules bind antigenic fragments of
processed proteins and present these on the surface of
APC for recognition by TCRs (1-3) . Whereas class II MHC
molecules function primarily to present antigen to CD4-
bearing T cells ofthe helper/inducer phenotype, classI MHC
presents antigen to CD8-bearing CTL.
Due to the central role of MHC in the generation of an
immune response, transgenic mice carrying human MHC
products (HLA) could provide an important model system
in which to assess the induction, prevention, or alteration
of an HLAassociated immune response. However, to be of
value, it must be established that antigen processing and pre-
sentation by murine cells reveal the same set of HLArestricted
antigenic epitopes recognized by human T cells, and that mu-
rine transgenic T cells respond to these epitopes in the con-
text of the HLA transgene product.
The demonstration by Gomard et al. (4) that HLA-A2-
or HLAAll-transfectedmurine P815 cells could serve as targets
for human antiviral CTL indicated that at least some of the
epitopes displayed by human APC are generated and presented
by murine cellsexpressing HLA molecules. However, success
in obtaining in vivo induced responses in transgenic mice
expressing HLA molecules has been limited. Responses
against influenza and Sendai virus have been obtained in trans-
genic mice carrying HLA-CW3 class I or both HLAB27
and human a2-microglobulin (02M)i (5-7). Other workers
using HLA-A2 transgenic mice have reported poor in vivo
priming (8, 9), despite the fact that the A2 molecule could
serve as an alloantigen for recognition by human CTL (9).
The lack ofdetectable murine HLAA2-restricted responses
might be due to species-specific differences in MHC mole-
cules that preclude efficient recognition by the murine TCR.
It is possible that the variable region genes of the TCR have
evolved to recognize the a1 and c12 domains ofMHC mole-
cules ofthe species. Alternatively, considering the significant
role of accessory molecules such as CD8 in repertoire selec-
tion (10, 11), TCR capable ofbeing restricted by xeno MHC
might be present but not selected in the thymus due to poor
interaction between the 0 domain of HLA-A2 and murine
CD8 (12, 13).
To discriminate between these possibilities, we have pro-
duced murine transgenic lines that express a chimeric class
I molecule composed of the al and a2 domains of HLA-
A2.1 and the 0 domain of H-2Kb(A2.1/Kb). In such mice,
a species-matched interaction between CD8 and its ligand
on the 0 domain of class I molecules should occur, thus
permitting assessment of the clonotypic TCR.
We show that A2.1/Kb transgenic mice can be primed in
1 Abbreviation used in this paper . 0ZM, /32-microglobulin.
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restricted CTL. Moreover, both epitoperecognition and fine
specificity ofmurine A2.1-restricted CTLare similar to those
definedfor humanT cells (14-16). Theseresults indicate the
utility of this system as a model for human T cell recogni-
tion of viral antigens and support the conclusion that even
in xenogeneic combinations, determinant selectionby MHC
is a major factor in dictating the antigen-specific TCR
repertoire.
Materials and Methods
Mice.
￿
C57BL/6, B10.D2, and BALB/c mice were purchased
from thebreeding colony ofScrippsClinic andResearch Foundation.
Production andDetectionof TransgenicMica
￿
Transgenic mice were
produced using a standard protocol (17) by injecting theA2.1/Kb
chimeric gene (12) into fertilized eggs obtained by crossing
(C57BL/6 x DBA/2)F1 mice. Transgenic lines were established
from mice carrying the transgeneas detected by tail DNA dotblot
analysis. Two transgenic lines, 66 and 372, were selected forthese
studiesbased on cell surface expression of the transgeneproduct.
To detect cell surface expression of A2.1/Kb, spleen cells or pe-
ripheral blood (-0.5 ml) collected from the tail vein of test mice
were treated with Tris-buffered ammonium chloride (5 ml) to lyse
redbloodcells. Cellswere washed and resuspended in RPMI 10%
supplemented with 2.5 Ng/ml Con A, 250 ng/ml ionomycin, 3
ng/mlPMA, and 5% culture supernatant of Con A-activated rat
splenocytes. Samples were incubated at 3 x 106 cells/well in a
volume of 2 ml for 3 d at 37°C in a humidified 5% C02 at-
mosphere.
A2.1 or A2.1/Kb cell surface expression was assessed by flow
cytometry (FRCSIV*; Becton Dickinson & Co., Mountain View,
CA)using abiotinylated HLAA2.1-specific mAb, MA2.1(18), and
PE-conjugated streptavidin (Biomeda, Foster City, CA). A2.1 ex-
pression was compared to H-2 expression on either Con A-acti-
vatedor nonactivated spleen cells using the appropriate mAbs and
a Fc fragment-specific, F(ab')2 FITC-conjugated goat anti-mouse
IgG(Pel-Freeze Biologicals, Rogers,AR). TheclassI-specific mAbs
used were: MA2.1 (A2.1-specific) (18), 34 .2.12S (H-2D'-specific)
(19), and 28.14.85 (H-21)b-specific) (20). Cellswere analyzed using
a flow cytometer.
Line 372 was maintained by backcrossing to B10.D2 and line
66 by backcrossing to C57BL/6.
Tumor Cell Lines.
￿
The following tumor cell lines were used
both as stimulator cells or target cells in cytotoxicity assays: E14
murine thymomacellsoriginally derived from C57BL/6 mice; EIr4
cells stably transfected with the A2.1/Kb chimeric gene (12);
Jurkat human T cell leukemia cells that are HLA A2.1 negative;
and stable transfectants ofJurkat expressing A2.1 or A2.1/Kb (12);
and aB10D2-derived SV40-transformed cell line. All cell lines were
grown in RPMI 1640 containing 10% FCS, 2 MM L-glutamine,
50 P,g/ml gentamicin, and 5 x 10 -5 M 2-ME (RPMI 10%).
Transfected lineswere grownin RPMI 10%, containing400lAg/ml
of G418 sulfate (Gibco Laboratories, Grand Island, NY) and were
periodically checked to ensure stability of the phenotype.
Peptides. Matrix peptide 55-73 (sequence: LTKGILGFVFT
LTVPSERG) and a series of truncated peptides were synthesized
on a peptide synthesizer (430A; Applied Biosystems, Foster, CA)
as previously described (21) . The peptides were then purified by
reversed-phase HPLC. Thepurity of thepeptides was substantiated
by amino acid sequence and/or composition analysis. They were
routinely >95% pure after HPLC. The index peptide 55-73 was
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substituted in the later experiments by the more active 57-68
peptide.
In VitroSecondaryResponses.
￿
Mice wereprimed intraperitoneally
with 300 hemagglutinating units of A/PR/8/34 influenza virus
(PR8) in the form of allantoic fluid. After 3 wk, cultures were
established in 24-well plates as previously described (22). Briefly,
spleen cells from primed mice (5 x 106/well) were cultured with
syngeneic irradiated (3,000 rad), PR8-infected (3 x 106/well)
spleen cells. After 6 d, effector cells were assayed for cytotoxicity.
CTL LinesandClones.
￿
Aftertwo in vitro restimulations with
PR8-infected spleen cells, transgenic CTL lines were maintained
by weekly restimulations with either: (a)Jurkat A2.1/Kb cells that
were irradiated (20,000rad), pulsed for 1 h at 37°C in thepresence
of 55-73 matrix peptide (15 AM), and washed three times
(1A2.1/Kb-M); or (b) EIL4 A2.1/Kb cells that were irradiated
(20,000 rad), infected with 50 HAU of PR8/ml for 1 h at 37°C,
and washed three times (EIT4A2.1/Kb-PR8). These stimulator
cells were used at a concentration of 0.1-0.2 x 106/well in the
presence of irradiated (3,000 rad) H-2 congenic feeder splenocytes
(3 x 106/well) in RPMI 10% supplemented with 5% rat Con
A supernatant. Clones were derived from theCTLline 66 by lim-
iting dilution using EIr4 A2.1/Kb-PR8 as stimulators in the pres-
ence of irradiated C57BL/6 feeder splenocytes. Clones were de-
rived from CTL lines 372-37-38 and 372-219 by limiting dilution
using JA2.1/Kb-M stimulators in the presence of B10D2 feeder
splenocytes. Clones have been kept by restimulationwith the stimu-
lator cells used for their derivation.
Cytotoxicity Assay.
￿
1.2 x 106 target cells were incubated at
37°C in the presence of 150 ACi of sodium "Cr chromate for 90
minin the presence or absenceof65 HAU of PR8during labeling.
Cellswere washed three timesandresuspended in RPMI containing
10% FCS. Matrix peptide (10 AM) was added either during 5iCr-
labeling (pulsed cells) or during thelyticassay at the finalconcen-
trations indicated in the text. For theassay, 10^ "Cr-labeled target
cellswere incubated with different concentrations of effector cells
in a finalvolume of200Al in U-bottomed 96-well plates. Superna-
tants were removedafter6 h at 37°C, andthepercent specific lysis
was determined by the formula: percent specific release = 100 x
(experimental release - spontaneous release)/(maximum release
- spontaneous release).
Results
Expression ofA2.1/Kb on Transgenic Spleen Cells.
￿
Spleno-
cytes isolated from line 66 and372 transgenic mice were ana-
lyzedby comparative cytofluorometry forthesurfaceexpres-
sion of HLAA2.1 and endogenous class I molecules (Db for
line 66 or Dd for line 372). Only 50% of line 66 spleen cells
expressed A2.1/Kb at -40% of thelevel of the endogenous
H-2Db (Fig. 1 A). Analysis of purified lymphocyte subsets
from line 66 demonstrated that only 50% of either B or T
lymphocytes were positive (datanot shown). Although 100%
of lymphocytes from line 372expressed the transgene, it was
present at only 10% the level of the endogenous H-21)d
(Fig. 1 C). However, after Con A stimulation, the expres-
sion of A2.1/Kb increased proportionally more than the
expression of the endogenous H-2, reaching 70% of the
H-21)b level in line 66 and 30% of the H-2Dd level in line
372 transgene blast cells (Fig. 1, B and D). No binding o£
anti-HLA antibody was observed for control spleen cellsde-
rived from H-2 congenic animals not expressing the trans-
gene product (data not shown) .B 0
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A.2/Kb Can Act as a Restriction Element. Splenocytes
from line 372 transgenic mice (H-2d; A2.1/Kb) primed with
PR8 influenza virus were restimulated in vitro and tested for
their ability to recognize viralantigens presented by the trans-
gene product. Since it has been shown that the influenza ma-
trix peptide 55-73 is the major determinant recognized in
conjunction with A2.1 in the human response (15), target
cells included both PR8-infected and matrix peptide-pulsed
target cells. Fig. 2 shows the results obtained using spleno-
cytes from 372 mice. Specific lysis of PR8-infected EIr4-
A2.1/Kb (H-2b; A2.1/Kb) cells (Fig. 2 A) indicated that 372
transgenic mice were able to generate an A2.1/Kb-restricted,
anti-PR8 CTL response; moreover, Elr4-A2.1/Kb cells
pulsed with the influenza matrix peptide were recognized
by the effector cells as efficiently as the PR8-infected targets,
suggesting that at least some of the CTL were specific for
the same antigenic determinants as detected after influenza
infection in humans (14, 15). Similar analysis usingJurkat
cells transfected with A2.1/Kb as targets (Fig. 2 B) revealed
a high level of specific lysis that required expression of the
A2.1/Kb molecule as well as the matrix peptide. The
influenza-primed transgenic spleen cells were also able to lyse
PR8-infected Jurkat A2.1/Kb cells (data not shown) .
Analysis of the specific lytic activity of splenocytes from
each ofthree additional PR8-primedtransgenic 372 mice con-
sistently revealed matrix peptide-specific lysis of Jurkat
A2.1/Kb target cells, albeit to a lesser extent than the specific
lysis obtained on H-2-bearing target cells (Table 1). Indeed,
3-10 times more effector cells were required to obtain lysis
of matrix-coated Jurkat A2.1/Kb targets equivalent to the
level obtained using PR8-infected B10D2 targets. However,
considering that PR8 infection of H-2d cells generates sev-
eral CTL epitopes (23), the magnitude of the CTL response
restricted by the transgene appears to be in the same range
as that restricted by endogenous H-2. Unprimed 372 mice
did not yield specific effectors, ruling out the possibility that
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Figure 1.
￿
Comparison of cell surface expression of
A2.1/Kb and endogenous H-2 on transgenic spleen cells.
Resting (A and C) or Con A-activated (B and D) spleen
cells from line 66 (A andB) or 372 (C and D) transgenic
mice wereanalyzed by cytofluorometry usingA2.1-specific
antibody MA2.1 (--); H-213b-specific antibody 28
14-85 (. . .
￿
); the H-213d-specific antibody 34-2-12S
(. . . . .); or no first antibody (- - - - - - -). The FITC-
labeled second antibody was specific for the IgG Fc
fragment.
1 .5 :1 5 :1 15:1 50:1
E:T Ratio
Figure 2.
￿
In vivo priming of influenza-specific HLA-A2.1/Kb-restricted
transgenic CTL. Pooled splenocytesfrom two PR8-immunized372 trans-
genic mice were restimulated in vitro with irradiated PR8-infected line
372 spleen cells. After 6 d, effector cells were assayed for lytic activity
in a 6-h s1Cr release assay. (A) EIr4 A2.1/Kb cells, untreated (p), PR8-
infected (*), or pulsed with matrix peptide 55-73 (EI). (B) Jurkat
A2.1/Kb cells, untreated (p) or pulsed with matrix peptide 55-73
or Jurkat cells untreated (p) or pulsed with matrix peptide 55-73 (~).Table 1.
￿
Lytic Activity of In Vivo Primed, HLA
A2.1/K6-restricted CTL from Individual Mice
Percent specific s1Cr release from
target cells"
Spleen cells from three PR8-primed line 372 transgenic mice were re-
stimulated in vitro with irradiated PR8-infected line 372 spleen cells, and
6 d later, CTL effector cells were assayed for lytic activity as described
in Materials and Methods.
As described in Materials and Methods.
t Target cells were either untreated or pulsed with matrix peptide 55-73
as described in Materials and Methods.
$ Target cells were either untreated or infected with PR8 virus as
described in Materials and Methods.
the CTL were being primed in vitro instead ofin vivo (data
not shown).
These results indicate that the 372 transgenic line can be
primed in vivo with PR8 influenza virus, leadingto the gener-
ation of influenza-specific A2.1/Kb-restricted CTL, and that
a portion of theresponse is directed toward the major human
A2.1-restrictedinfluenza epitope, i.e., matrix peptide 55-73.
Studies carried out using the A2.1/Kb-expressing 66 trans-
genic line gave similar results (data not shown).
Matrix Peptide Is the Major EpitopeRecognized by A2.1/Kb-
restricted Virus-specific CTL Clones from Transgenic Mice. To
determine what proportion of PR8-specific, A2.1-restricted
murine CTL recognized the matrix peptide, lyticassays were
carried out after clonally distributing spleen cells from PR8-
primed 372 transgenic mice. A total of 19 A2.1-restricted,
PR8-specific clones derived from two individual 372 mice
were analyzed. 17 of these clones were specific forthematrix
peptide suggesting that thedominant A2.1-restricted response
in the transgenic mice is directed towards the matrix pep-
tide. Only two clones (nos. 13 and 17) gave a response on
PR8-infected targets that was sufficiently low when tested
on matrix peptide targets to suggestrecognition of adifferent
influenza antigen (Table 2).
Primingfor A2.1-restricted Murine CTL Does Not Occuron
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Table 2.
￿
Matrix Peptide 57-68 Is the Major Epitope Recognized
by A2.1/K6-restricted Virus-speck CTL Clones from
Transgenic Mice
Percent specific "Cr release
from EL-4 A2.1/Kb
target cells'
Spleen cells derived from two PR8-primed 372 mice were restimulated
in vitro with irradiated PR8-infected syngeneic splenocytes for 7 d and
then plated by limiting dilution onto EL-4 A2.1/Kb-PR8 and B10 D2
feeder cells. After 7 d, cultures were split three ways and assayed for
their specificity. Wells were considered positive for the presence of an
A2.1/Kb-restricted PR8-specific CTL clone if lysis was 10% or less on
uninfected cells and 20% or more on infected cells. Wells were consi-
dered to contain clonally distributed cells if 20% or fewer wells plated
at a given cell concentration were positive.
" As described in Materials and Methods. Target cells were untreated,
PR8 infected, or in the presence of matrix peptide 57-68 at 1.3 pM.
H-2.
￿
To ensure that murine A2.1-restricted CTL did not
derive from the murine H-2-restricted PR8-specific response
dueto a fortuitous crossreaction, A2.1-restricted matrix-specific
CTL clone (372-37-38-3), or CTL lines obtained by selec-
tive restimulation with the matrix peptide(372-219 and 66),
were tested on A2.1-negative H2-congenic infected target cells.
As seen in Table3, all linestested specifically killed theA2.1-
bearing target only. No lysis was obtained on PR8-infected
H-2 congenic target cells.
Fine Specificity Analysis ofA2.1/K6-restricted CTL Clones.
The fine specificities of human T cells that respond to the
influenza matrix peptide 55-73 have been investigated ex-
tensively by others (16). To determine whether the fine
Line 372 mice
(animal no.) E/T -
Jurkat
A2.1/Kb$
Matrix
peptide
B10 D25
PR8
Line 372 mice
(animal no .)
350
213 50:1 15 45 26 72
15:1 8 29 11 80
5:1 5 13 2 38
214 50:1 20 57 13 60
15:1 13 40 9 70
5:1 5 21 1 32
215 50:1 27 66 22 73
15:1 14 57 8 71
5:1 4 32 2 55 346
Clone no. - PR8 Matrix peptide
1 0 33 24
2 3 48 41
3 6 35 29
4 4 51 40
5 1 21 9
6 2 35 34
7 5 47 37
8 10 61 48
9 4 61 51
10 3 28 21
11 2 21 12
12 5 40 24
13 3 29 5
14 4 40 14
15 3 47 12
16 8 57 35
17 7 29 8
18 6 40 16
19 7 40 27Table 3.
￿
A2.1-restricted Transgenic CTL Do Not Recognize
Influenza Antigens in the Context of Endogenous H-2
Percent specific "Cr release from
target cells"
Jurkat
A2.1/Kb B10D2 EL-4
Cell lines
￿
E/T UN PR8 UN PR8 UN PR8
372-37-38-3t
(H-2d)S
372-2194
(H-2d)
BALB/c-PR811
(H-2d)
66t
(H-2b)
C57BL/6-PR811
(H-2b)
" As described in Materials and Methods.
4 CTL lines and clones were derived and maintained as described in
Materials and Methods.
S Murine H-2 haplotype.
II BALB/c-PR8 and C57BL/6-PR8 effector cells were obtained from im-
mune spleen cells after two in vitro restimulations with syngeneic
PR8-infected spleen cells as described in Materials and Methods.
specificities of murine A2.1-restricted, virus-specific CTL
clones were similar to that observed for human T cells, three
clones (two originating from transgenic line 372 mice and
one from a line 66 mouse) were tested for their lytic activity
on Jurkat A2.1/Kb target cells in the presence of a series of
truncatedmatrix peptides (56-68, 57-68, 57-73, 58-73, and
59-73). As shown in Fig. 3, analysis of theseclones allowed
us to detect two fine specificities distinguishable on thebasis
of recognition of peptide 59-73. Although this peptide was
the one most efficiently recognized by clone 372-219-11 (in-
ducing optimal lysis at <0.01 AM), it was not recognized
by the other two clones. Despite the clear-cut difference in
therecognition ofpeptide 59-73, all threeclones recognized
peptide 57-68 comparably with lysis obtained at -0.1 AM
peptide. The other peptides were recognized less well and
clones differed by an order of magnitude in the concentra-
tion of peptide (0.1-1 AM) required for target cell recogni-
tion. Thus, murine A2.1/Kb-restricted CTL clones displayed
clonal heterogeneity.
Recognition ofA2.1 as Compared with A2.1/K6-transfected
Cells. It was of interest to determine whether theA2.1/Kb-
restricted T cells generated in virus-primed A2.1/Kb trans-
genic mice were also able to recognizetarget cells expressing
the native HLA-A2.1 molecule. CTL lines and clones iso-
lated from both the 372 and the 66 transgenic A2.1/Kb mu-
rine lines were tested for their capacity to specifically lyse
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Figure 3.
￿
Fine specificity analysis ofA2.1-restricted, virus-specific mu-
rine CTL clones. Lysis ofJurkat A2.1/Kbcells was measured in thepres-
ence oftruncatedmatrix peptide56-68((]),57-68(*), 57-73(p), 58-73
(0), and59-73 (N)at theconcentrations indicated. Clones 372-37-38-3,
66-11, and372-219-11 were derivedas describedin Materials andMethods.
The E/T was 5:1.
Jurkat cells that express either A2.1 or A2.1/Kb in the pres-
ence or absence of matrix peptide antigen.
Theeffector cells used in this experiment represented long-
term cell lines or T cell clones. As documented by theresults
presented in Table 4, both Jurkat A2.1 and Jurkat A2.1/Kb
targets were able to present peptide for CTL recognition.
Ofinterest however, consistently lower levels ofkilling were
obtained with Jurkat A2.1 targets. This was not due to a
1.25:1 1 21 0 0 ND
20:1 6 43 1 0
1.5 :1 3 30 0 0 ND
24 :1 12 46 0 3
2.4:l ND 3 16 ND
22 :1 15 44
e e
d
1.6 :1 0 42 0 1 d
26 :1 6 49 6 5
3.3 :1 1 45
30:1 12 65
U
e a
NTable 4.
￿
Recognition ofHLA A2.1 : as compared to A2.1/Kb-transfectedJurkat Cells
lower level of A2.1 expression, as FACS® analysis revealed
slightly higher levels of A2.1 than A2.1/Kb molecules on
these transfected lines (data not shown).
Discussion
The two major goals of the present studywere: (a) to de-
termine whether substitution ofthe 0 domain ofA2.1 with
its murine counterpart would override some ofthe difficulty
in generating antigen-specific murine CTL restricted by HLA
A2.1; and (b) ifa response was obtained, to determine whether
the murine response entailed recognition of the same anti-
genic epitopes previously defined in the corresponding HLA-
A2.1-restricted response in humans.
Our findings demonstrate that virus infection of A2.1/Kb
transgenic mice does lead to generation of A2.1-restricted,
influenza-specific CTL. That the actual priming in vivo
resulted from antigen recognition in the context of A2.1/Kb
and not the murine class I molecules was confirmed by the
fact that none of the A2.1-restricted lines recognized PR8-
infected nontransgenic H-2d or H-2b targets. Within both
Percent specific "Cr release from target cells'
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As described in Materials and Methods. Target cells were either untreated or in the presence of matrix peptide 57-68 at a concentration of 6 .7 uM.
t CTL lines and clones were derived and maintained as described in Materials and Methods.
the 66 and 372 transgenic lines, the capacity to respond to
influenza virus in the context of A2.1/Kb was consistent
from mouse to mouse, suggesting differences in the basal level
of expression of the transgene, as exists in these lines, did
not substantially affect responsiveness.
These results are in contrast to previous findings by several
groups who have found only weak (9) or no (8) A2.1-restricted
virus-specific responses in transgenic mice. Thus, it is likely
that the presence of the murine 0 domain greatly facilitated
A2.1-restricted recognition of antigen. This is in agreement
with previously published results, which have demonstrated
that unlike the native A2.1 molecule, the chimeric A2.1/Kb
molecule was effective in stimulating a primary in vitro re-
sponse by murine CTL (12, 13).
The mechanism by which the murine 0 domain increases
responsiveness in the context of A2.1 may involve several
different components. Most prominent is the potential role
of the 0 domain of Kb in facilitating interaction with mu-
rine CD8. Class I-CD8 interaction is important for efficient
repertoire selection in the thymus (10, 11) for activation of
CTL precursors (24), and for CTL recognition oftarget cells
Clones E/T
Jurkat
Untransfected
M
Jurkat
A2 .1
M -
Jurkat
A2.1/Kb
M
372-37-38-3t 0.3:1 3 1 0 7 1 37
1:1 4 2 2 21 2 68
3:1 5 7 3 44 5 85
372-37-38-5t 0.3:1 3 3 1 4 1 26
1:1 9 5 1 15 4 53
3:1 15 11 4 40 9 88
372-219-114 0.3:1 1 1 0 27 2 42
1:1 1 2 2 52 0 66
3:1 2 2 2 81 2 88
66-11t 0.3:1 0 0 0 36 0 58
1:1 0 3 0 72 0 92
3:1 7 13 2 93 3 98
372-2191 0.3:1 2 1 1 35 1 52
1:1 3 3 2 57 5 78
3:1 6 6 4 78 9 90
66t 0.3:1 1 0 2 21 1 50
1:1 4 0 2 43 0 72
3:1 3 7 1 68 2 89(25-28). The residues in class I critical for CD8 binding have
been mapped within the 0 domain. It is known that slight
sequence variation in the 0 domain can greatly influence
interaction with CD8 (26-28, 30). Studies that demonstrated
the importance of a murine 0 domain in enhancing recog-
nition by murine A2.1-specific CTL clones (12) also provided
evidence that those clones most affected were the ones most
dependent on CD8-class I interaction in their recognition
of target cells. Thus, it is likely that in vivo utilization of
the A2.1 molecule has been facilitated by providing it with
a murine 0 domain, thereby permitting optimal interac-
tion with the murine CD8 molecule. Interestingly, murine
HLAB27 molecules have been shown to function in both
a primary xenogeneic MLC (31) and as a restriction element
in transgenic mice (6, 7). It is possible that results obtained
using different HLA class I molecules may vary due to se-
quence differences in the 0 domains that affect the efficiency
of interaction with the murine CD8 molecule.
In addition to its role in CD8 binding, the 0 domain
may also influence classI MHC function through its binding
to 02M. Association with 02M is required for efficient trans-
port (32, 33), folding (34, 35), and peptide binding (36) by
class I. Moreover, heterologous 02M induces conformational
changes in class I that can be detected by mAbs (37). Recent
data also suggest that in some cases 02M may participate in
the selection of peptides for association with class I (38). How-
ever, interaction of murine 02M with the 0 domain of
HLAA2.1 does not appear to grossly affect the ability ofHLA
A2.1 to serve as a restriction element for influenza virus-de-
rived determinants since murine cells transfected with A2.1
serve as targets for influenza-specific, A2.1-restricted murine
or human CTL clones (4; and A. Vitiello's, unpublished ob-
servations). However, it is difficult to rule out quantitative
effects that may be important for CTL priming in vivo.
The A2.1/Kb transgene contained the transmembrane and
cytoplasmic portions of Kb. Although hypothetical at this
time, it is possible these regions may also play an important
role during T cell maturationor activation, perhaps by medi-
ating signals required for production of interleukins, as has
been reported for class 11 molecules (39). If this were the case,
then the presence of Kb as opposed to A2.1 sequence may
have facilitated such signaling in murine cells.
The potential usefulness of HLA transgenic mice for vac-
cine and drug development depends on the ability of the mu-
rine TCR repertoire to recognize the same antigenic deter-
minants recognized by human T cells. The matrix protein
is the dominant influenza virus molecule recognized by A2.1-
restricted human CTL (14). Recent work has demonstrated
that the majority of the A2.1-restricted CTL recognize de-
terminants within the matrix peptide represented by amino
acids 55-73 (15). In the present studies, an epitope, or epi-
topes, present in matrix peptide 55-73 dominated the PR8-
specific A2.1/Kb-restricted response. Analysis at the clonal
level revealed this peptide specificity by the majority of the
influenza-reactive clones (17/19). Several clones (nos. 5, 12,
14, and 15) appeared to recognize the matrix peptide less well
than viral-infected cells. Since neither the quantity nor the
size of the antigenic peptide generated upon PR8 infection
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of target cells is known, strict qualitative or quantitative com-
parisons between targets sensitized with PR8 vs. synthetic
peptide are difficult. Clones 13 and 17 clearly did not recog-
nize the 55-73 matrix peptide, suggesting that a different
viral epitope was recognized by some clones.
As with influenza-specific A2.1-restricted human CTL (16),
the transgenic CTL response contained clones with different
fine specificities, as detected using truncated matrix peptides.
The peptide most efficiently recognized by the murine and
human T cell clones was 57-68. This may reflect higher
binding affinity by the peptide for A2.1 than either the longer
or truncated versions. One of the murine T cell clones (clone
372-219.11) lysed target cells sensitized with peptide 59-73
much more effectively (>100-fold) than targets sensitizedwith
the other peptides. This phenotype cannot be explained simply
on the basis of enhanced peptide binding since two of the
clones did not recognize this peptide at all. Rather, it more
likely reflects a true difference in fine specificity by TCRs.
It is noteworthy that in the studies of the fine specificity of
human T cells (16), one of the clones displayed a similar rec-
ognition pattern.
While the binding of antigenic peptides to MHC mole-
cules has been recognized as a critical step in antigen presen-
tation, several important differences between species could
have skewed the response away from the matrix 55-73 deter-
minant. Both the positive and negative T cell selection events
that occur during ontogeny may have produced distinct T
cell repertoires in humans and transgenic mice. Also, since
it is likely that peptides derived from "self' as well as "non-
self" proteins can compete for MHC binding (40-42), the
presence ofa different array ofpeptides in the mouse (as com-
pared with human) could have prevented the association of
the matrix peptide with the A2.1 molecule in vivo. Indeed,
in light of these potentially important differences, it is sur-
prising to find such a strong similarity between the murine
and human specificity repertoires.
The ability of transgenic mice to mount a vigorous
A2.1/Kb-restricted response argues that there is sufficient
diversity in the murine TCR repertoire to supply a variety
of receptors specific for antigen in the context of an HLA
molecule. Nevertheless, it would be of interest to compare
the actual number of different TCR genes used in the mu-
rine response with the repertoire ofhuman TCR specific for
the same antigen.
In conclusion, our demonstration that A2.1/Kb transgenic
mice can be primed in vivo with influenza virus and that
the response generated is specific for virtually the same epi-
topes as those recognized by human influenza-specific CTL
points to the potential of HLA transgenic mice as an impor-
tant model for the study ofdeterminants recognized by human
T cells. Although additional antigens restrictedby HLAA.2
as well as different MHC molecules must be examined in
order to determine the limitations of this model system, trans-
genics in which HLA molecules appear to function efficiently
as restricting elements represent an important resource for
the identification of HLArestricteddeterminants and for the
development of molecules that enhance or decrease antigen-
specific, HLA-restricted immune responses.References
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